Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery

Abbott Laboratories (NYSE:ABT) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 2, the price target on Abbott Laboratories (NYSE:ABT) was reduced from $169 to $142 by Barclays analyst Matt Miksic. The analyst reiterated his Overweight rating on the stock, which offers a revised upside potential of almost 27%. Abbott Laboratories (ABT) Likely to Benefit From Nutrition Segment Recovery Miksic’s revisions were based on deflated forecasts and target multiple for ...